$20.22
0.80% today
Nasdaq, Aug 22, 10:08 pm CET
ISIN
US8036071004
Symbol
SRPT

Sarepta Therapeutics, Inc. Stock price

$20.22
+6.61 48.51% 1M
-85.34 80.85% 6M
-101.37 83.37% YTD
-121.21 85.70% 1Y
-87.51 81.23% 3Y
-120.98 85.68% 5Y
-12.66 38.50% 10Y
+7.08 53.88% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.16 0.80%

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$2.3b
Net debt
$339.3m
Cash
$800.1m
Shares outstanding
97.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.8 | 1.0
EV/Sales
0.9 | 1.2
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
38.6%
Return on Equity
15.4%
ROCE
0.0%
ROIC
-0.1%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$2.5b | $2.0b
EBITDA
$1.5m | $-514.5m
EBIT
$-932.0k | $-393.2m
Net Income
$-58.0m | $-407.5m
Free Cash Flow
$-454.0m
Growth (TTM | estimate)
Revenue
64.9% | 3.5%
EBITDA
-96.2% | -333.3%
EBIT
-102.5% | -280.3%
Net Income
-222.5% | -273.2%
Free Cash Flow
14.0%
Margin (TTM | estimate)
Gross
79.3%
EBITDA
0.1% | -26.1%
EBIT
0.0%
Net
-2.3% | -20.7%
Free Cash Flow
-18.3%
More
EPS
$-0.5
FCF per Share
$-4.6
Short interest
25.1%
Employees
1k
Rev per Employee
$1.4m
Show more

Is Sarepta Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Sarepta Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

12x Buy
33%
19x Hold
53%
5x Sell
14%

Analyst Opinions

36 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

Buy
33%
Hold
53%
Sell
14%

Financial data from Sarepta Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,482 2,482
65% 65%
100%
- Direct Costs 514 514
192% 192%
21%
1,967 1,967
48% 48%
79%
- Selling and Administrative Expenses 564 564
9% 9%
23%
- Research and Development Expense 1,402 1,402
82% 82%
57%
1.54 1.54
96% 96%
0%
- Depreciation and Amortization 2.47 2.47
4% 4%
0%
EBIT (Operating Income) EBIT -0.93 -0.93
102% 102%
0%
Net Profit -58 -58
222% 222%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Sarepta Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sarepta Therapeutics, Inc. Stock News

Neutral
PRNewsWire
about 3 hours ago
NEW YORK , Aug. 22, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline. So What: If you purchased Sarepta Therapeutics securities during the Class Peri...
Positive
Seeking Alpha
about 6 hours ago
Sarepta Therapeutics is trading at a huge discount to previous enterprise value, with significant upside potential as the situation stabilizes in the near term. ELEVIDYS may be able to regain the non-ambulatory segment in the future, leading to further opportunity. Company restructuring sets up a realistic shot of turnaround.
Neutral
GlobeNewsWire
about 6 hours ago
SAN FRANCISCO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT), triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ELEVIDYS as a safe and effective treatment with a clear path to broader regulatory approval.
More Sarepta Therapeutics, Inc. News

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Head office United States
CEO Douglas Ingram
Employees 1,372
Founded 1980
Website www.sarepta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today